TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue opioid analgesia using fentanyl
Description: intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue opioid analgesia using fentanyl
Description: intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue opioid analgesia using fentanyl
Description: intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline
Study: NCT04872283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: great toe (1st metatarsophalangeal joint) fusion
Description: Great Toe joint fusion surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ketorolac
Description: Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Pill
Description: Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5/325mg Oxycodone-Acetaminophen
Description: Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5/325mg Oxycodone-Acetaminophen
Description: Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
Study: NCT02160938

Intervention type: OTHER
Intervention: 3-year follow-up
Description: When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~* The Vineland-II Adaptive Behavior Scale (VABS)~* Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~* Children will also be photographed (for review by the study dysmorphologist)
Study: NCT01132508

Intervention type: DEVICE
Intervention: Norian Drillable Bone Void Filler
Description: Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
Study: NCT01716273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Granulated Sugar
Description: 30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Granulated Sugar
Description: 30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debridement Dressing
Description: 1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Debridement Dressing
Description: 1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue atropine administration
Description: atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously when heart rate \< 50
Study: NCT01911741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue atropine administration
Description: atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously when heart rate \< 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue atropine administration
Description: atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously when heart rate \< 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue urapidil administration
Description: urapidil (Ebrantil 25, Takeda PHARMA, Japan) in a dose of 10 mg will be administered intravenously when DAP \> 110 mmHg or SAP \> 200 mmHg
Study: NCT01911741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study: NCT01020123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Different doses of AZD1656 administered to 5 groups of patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Different doses of AZD1656 administered to 5 groups of patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Different doses of AZD1656 administered to 5 groups of patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Different doses of AZD1656 administered to 5 groups of patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Different doses of AZD1656 administered to 5 groups of patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AZD1656 placebo and glipizide placebo administered to 1 group of patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Glipizide administered to 1 group of patients
Study: NCT02857868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Study: NCT01535885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytotoxic T Lymphocytes
Description: Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
Study: NCT04434508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic right hemicolectomy with CME and central v
Description: laparoscopic right hemicolectomy with CME and central v

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open right hemicolectomy with CME and central v
Description: Open right hemicolectomy with CME and central v
Study: NCT04289909

Intervention type: OTHER
Group type: OTHER
Intervention: Adaptive Optics Ophthalmoscopy (AOO)
Description: AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)

Intervention type: OTHER
Group type: OTHER
Intervention: Adaptive Optics Ophthalmoscopy (AOO)
Description: AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
Study: NCT02866643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel-Immediate
Description: The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel-Delayed
Description: The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
Study: NCT01162200

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy
Description: 3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
Study: NCT03684746

Intervention type: OTHER
Intervention: No Intervention
Description: It is an observational Study with staff

Intervention type: OTHER
Intervention: No Intervention
Description: It is an observational Study with staff
Study: NCT00825240

Intervention type: BEHAVIORAL
Intervention: One-time Questionnaire + Recorded Qualitative Interview
Description: One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
Study: NCT02394769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aspirin
Study: NCT04066374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
Study: NCT00587093

Intervention type: OTHER
Group type: OTHER
Intervention: CA 125 and CT scan
Description: Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
Study: NCT03778671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Patients will receive Levobupivacaine 5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
Study: NCT01273259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA Treatment
Description: DHEA : 200 mg/day hard gelatine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA Treatment
Description: DHEA : 25 mg/day hard gelatine capsule
Study: NCT04328987

Intervention type: PROCEDURE
Intervention: cold snare polypectomy
Description: Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.

Intervention type: PROCEDURE
Intervention: cold snare polypectomy
Description: Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
Study: NCT01683461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Counseling
Description: Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
Study: NCT03882632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fat Grafting for Fecal Incontinence
Description: Autologous adiopse tissue harvesting/grafting using Lipogems
Study: NCT03036267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Condition
Description: PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
Study: NCT01571843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm exercise program
Description: Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm exercise program
Description: Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walking program
Description: Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walking program
Description: Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
Study: NCT03847571

Intervention type: DRUG
Intervention: Acetazolamide
Description: Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
Study: NCT00641563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Infusion of dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Infusion of dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Infusion of remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Infusion of remifentanil
Study: NCT00934375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept (donepezil hydrochloride)
Description: 5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05076734

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Redraw for analysis of blood samples from healthy pregnant women
Description: If less than two fetal cells are recovered from maternal blood, a redraw is indicated
Study: NCT01715051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-serine
Description: The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
Study: NCT02097732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
Study: NCT00913601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic INTERSIM II - 3058
Description: Medtronic INTERSIM II - 3058 Impuls Generator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic INTERSIM II - 3058
Description: Medtronic INTERSIM II - 3058 Impuls Generator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic INTERSIM II - 3058
Description: Medtronic INTERSIM II - 3058 Impuls Generator
Study: NCT01654276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: One 40 mg tablet once a day for 6 months
Study: NCT03720925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TDI treatment
Description: The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
Study: NCT02053103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Tablet, 200 mg, twice daily, 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg, twice daily, 6 weeks
Study: NCT01317641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 administered orally daily
Study: NCT01631214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg tablet taken once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate 70 mg tablet taken once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Romosozumab
Description: Administered by subcutaneous injection once a month during the double-blind treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Alendronate
Description: Matching placebo tablet taken once a week during the double-blind treatment phase.
Study: NCT04518696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprachoroidal buckling
Description: Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures.
Study: NCT03994380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhDNAse Inhalation Solution
Description: rhDNAse 2.5 mg nebulizer daily for 4 weeks
Study: NCT05601349

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth-based strategy
Description: Teleducation course, based on the CPG recommendations

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telehealth-based strategy
Description: Teleducation course, based on the CPG recommendations